Navigation Links
SPI Pharma Gains Ground in Roquette Patent Dispute
Date:6/17/2010

WILMINGTON, Del., June 17 /PRNewswire/ -- On Friday June 11th, Chief Judge Gregory Sleet of the United States District Court for the District of Delaware issued an important pre-trial ruling in the long-running patent dispute between SPI Pharma and Roquette Freres.  

The court's ruling narrowly defined several key phrases contained in Roquette's patent claims, thereby dealing a significant blow to Roquette's allegations of patent infringement. Chief Judge Sleet issued his ruling after hearing extensive oral arguments in open court on May 11th. The case is scheduled to go to trial beginning October 4th.  

SPI Pharma's President, Rana Kayal, was very pleased with the decision: "This ruling by the court strongly supports our long-held position that SPI Pharma's Mannogem EZ and Pharmaburst® products do not infringe on Roquette's patent. SPI Pharma will continue to defend itself against Roquette's baseless allegations of patent infringement, and we look forward to presenting our case to the jury at the trial to be held in October."    

SPI Pharma is a global leader with sales in over 55 countries in the manufacture and marketing of antacid actives, excipients, drug delivery systems for tablets, soft gel capsules, fast-dissolve technologies, chewables, lozenges, and a variety of other patient-friendly dosage forms. SPI also specializes in drug development services. For more information, visit www.spipharma.com


'/>"/>
SOURCE SPI Pharma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
2. Pharmatek Adds Cytotoxic and High-Potent Drug Development Capabilities to San Diego Laboratory
3. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
4. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
5. Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court
6. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
7. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
8. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
9. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
10. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
11. Baxa Announces 2008 Dates for STAR Center Professional Pharmacy and Cleanroom Training
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/18/2017)... 2017 Research and Markets has announced the ... report to their offering. ... The report provides separate comprehensive analytics for the US, ... Rest of World. Annual estimates and forecasts are provided for the ... for these markets. Market data and analytics are derived from primary ...
(Date:2/17/2017)... Calif. , Feb. 17, 2017  Protagonist ... detailing data on its oral peptide drug candidates, ... Congress of the European Crohn,s and Colitis Organization ... Barcelona, Spain from February ... posters detail preclinical data on Protagonist drug candidates ...
(Date:2/16/2017)... Fla. , Feb. 16, 2017  MDNA ... revolutionizing the development of liquid biopsy tests based ... entered into an exclusive license agreement with its ... MDNA,s proprietary liquid biopsy test for prostate cancer, ... South Korea . This is the first ...
(Date:2/16/2017)... PALM BEACH, Florida , February 16, 2017 ... vastly improving with the infusion of innovative telemedicine ... patient monitoring services that are experiencing a boom ... evolve with the advancement of technologies, services and ... Technologies Inc. (OTC: RQHTF) (TSX-V: RHT), Cellectar Biosciences, ...
Breaking Biology Technology:
(Date:1/31/2017)... 2017  Spero Therapeutics, LLC, a biopharmaceutical company ... of bacterial infections, today announced it has acquired ... Pro Bono Bio Ltd (PBB) to bolster its ... forms of Gram-negative bacteria.   The assets acquired have ... PBB group company. "The acquisition of ...
(Date:1/24/2017)... 2017 Biopharm Reports has carried out ... of nuclear magnetic resonance spectroscopy (NMR). This involved ... current practices, developments, trends and end-user plans over ... and opportunities. These areas include growth in the ... and innovation requirements, hyphenated NMR techniques, main suppliers ...
(Date:1/19/2017)... 19, 2017 Sensory Inc ., ... security for consumer electronics, and i ... and cybersecurity solutions, today announced a global partnership ... institutions worldwide to bolster security of data sensitive ... user authentication platforms they offer, innerCore now offers ...
Breaking Biology News(10 mins):